When potentially dangerous high liver enzymes showed up in two asymptomatic participants during Third Harmonic Bio Inc.’s ongoing phase Ib study of the KIT inhibitor THB-001, the company decided to ...
Wall Street was sorting through two batches of news from Jasper Therapeutics Inc., which made public positive data from the phase Ib study called Etesian with KIT-targeting briquilimab in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results